Literature DB >> 29925484

Senolytic activity of piperlongumine analogues: Synthesis and biological evaluation.

Xingui Liu1, Yingying Wang1, Xuan Zhang1, Zhengya Gao1, Suping Zhang1, Peizhong Shi1, Xin Zhang1, Lin Song1, Howard Hendrickson1, Daohong Zhou2, Guangrong Zheng3.   

Abstract

Selective clearance of senescent cells (SCs) has emerged as a potential therapeutic approach for age-related diseases, as well as chemotherapy- and radiotherapy-induced adverse effects. Through a cell-based phenotypic screening approach, we recently identified piperlongumine (PL), a dietary natural product, as a novel senolytic agent, referring to small molecules that can selectively kill SCs over normal or non-senescent cells. In an effort to establish the structure-senolytic activity relationships of PL analogues, we performed a series of structural modifications on the trimethoxyphenyl and the α,β-unsaturated δ-valerolactam rings of PL. We show that modifications on the trimethoxyphenyl ring are well tolerated, while the Michael acceptor on the lactam ring is critical for the senolytic activity. Replacing the endocyclic C2-C3 olefin with an exocyclic methylene at C2 render PL analogues 47-49 with increased senolytic activity. These α-methylene containing analogues are also more potent than PL in inducing ROS production in WI-38 SCs. Similar to PL, 47-49 reduce the protein levels of oxidation resistance 1 (OXR1), an important oxidative stress response protein that regulates the expression of a variety of antioxidant enzymes, in cells. This study represents a useful starting point toward the discovery of senolytic agents for therapeutic uses.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  OXR1; Piperlongumine; ROS; Senescent cell; Senolytic agent

Mesh:

Substances:

Year:  2018        PMID: 29925484      PMCID: PMC6087492          DOI: 10.1016/j.bmc.2018.06.013

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  52 in total

1.  Inhibition of Bcl-2/xl With ABT-263 Selectively Kills Senescent Type II Pneumocytes and Reverses Persistent Pulmonary Fibrosis Induced by Ionizing Radiation in Mice.

Authors:  Jin Pan; Deguan Li; Yanfeng Xu; Junling Zhang; Yueying Wang; Mengyi Chen; Shuai Lin; Lan Huang; Eun Joo Chung; Deborah E Citrin; Yingying Wang; Martin Hauer-Jensen; Daohong Zhou; Aimin Meng
Journal:  Int J Radiat Oncol Biol Phys       Date:  2017-03-04       Impact factor: 7.038

2.  Synthesis of piperlongumine analogues and discovery of nuclear factor erythroid 2-related factor 2 (Nrf2) activators as potential neuroprotective agents.

Authors:  Shoujiao Peng; Baoxin Zhang; Xianke Meng; Juan Yao; Jianguo Fang
Journal:  J Med Chem       Date:  2015-06-26       Impact factor: 7.446

3.  Synthesis and evaluation of N-heteroaromatic ring-based analogs of piperlongumine as potent anticancer agents.

Authors:  Yu Zou; Chang Yan; Huibin Zhang; Jinyi Xu; Dayong Zhang; Zhangjian Huang; Yihua Zhang
Journal:  Eur J Med Chem       Date:  2017-06-27       Impact factor: 6.514

4.  Senescent intimal foam cells are deleterious at all stages of atherosclerosis.

Authors:  Bennett G Childs; Darren J Baker; Tobias Wijshake; Cheryl A Conover; Judith Campisi; Jan M van Deursen
Journal:  Science       Date:  2016-10-27       Impact factor: 47.728

5.  Oncogene-induced senescence as an initial barrier in lymphoma development.

Authors:  Melanie Braig; Soyoung Lee; Christoph Loddenkemper; Cornelia Rudolph; Antoine H F M Peters; Brigitte Schlegelberger; Harald Stein; Bernd Dörken; Thomas Jenuwein; Clemens A Schmitt
Journal:  Nature       Date:  2005-08-04       Impact factor: 49.962

Review 6.  Historical Spice as a Future Drug: Therapeutic Potential of Piperlongumine.

Authors:  Sahdeo Prasad; Amit K Tyagi
Journal:  Curr Pharm Des       Date:  2016       Impact factor: 3.116

7.  Design, Synthesis and Pharmacological Evaluation of Novel Piperlongumine derivatives as Potential Antiplatelet Aggregation Candidate.

Authors:  Yujun Wang; Jie Wang; Jiaming Li; Yanchun Zhang; Weijun Huang; Jian Zuo; Huicai Liu; Di Xie; Panhu Zhu
Journal:  Chem Biol Drug Des       Date:  2016-03-15       Impact factor: 2.817

Review 8.  Four faces of cellular senescence.

Authors:  Francis Rodier; Judith Campisi
Journal:  J Cell Biol       Date:  2011-02-14       Impact factor: 10.539

9.  Identification of a novel senolytic agent, navitoclax, targeting the Bcl-2 family of anti-apoptotic factors.

Authors:  Yi Zhu; Tamara Tchkonia; Heike Fuhrmann-Stroissnigg; Haiming M Dai; Yuanyuan Y Ling; Michael B Stout; Tamar Pirtskhalava; Nino Giorgadze; Kurt O Johnson; Cory B Giles; Jonathan D Wren; Laura J Niedernhofer; Paul D Robbins; James L Kirkland
Journal:  Aging Cell       Date:  2016-03-18       Impact factor: 9.304

Review 10.  Redox control of senescence and age-related disease.

Authors:  Akshaya Chandrasekaran; Maria Del Pilar Sosa Idelchik; J Andrés Melendez
Journal:  Redox Biol       Date:  2016-11-16       Impact factor: 11.799

View more
  13 in total

Review 1.  Cellular senescence in ageing: from mechanisms to therapeutic opportunities.

Authors:  Raffaella Di Micco; Valery Krizhanovsky; Darren Baker; Fabrizio d'Adda di Fagagna
Journal:  Nat Rev Mol Cell Biol       Date:  2020-12-16       Impact factor: 94.444

Review 2.  A guide to senolytic intervention in neurodegenerative disease.

Authors:  Suckwon Lee; Ellen Y Wang; Alexandra B Steinberg; Chaska C Walton; Shankar J Chinta; Julie K Andersen
Journal:  Mech Ageing Dev       Date:  2021-10-08       Impact factor: 5.432

Review 3.  Recent advances in the discovery of senolytics.

Authors:  Lei Zhang; Louise E Pitcher; Vaishali Prahalad; Laura J Niedernhofer; Paul D Robbins
Journal:  Mech Ageing Dev       Date:  2021-10-14       Impact factor: 5.432

4.  Discovery of the First-in-Class G9a/GLP Covalent Inhibitors.

Authors:  Kwang-Su Park; Yan Xiong; Hyerin Yim; Julia Velez; Nicolas Babault; Prashasti Kumar; Jing Liu; Jian Jin
Journal:  J Med Chem       Date:  2022-06-28       Impact factor: 8.039

Review 5.  Cellular Senescence: Molecular Targets, Biomarkers, and Senolytic Drugs.

Authors:  Natalie Kudlova; Juan Bautista De Sanctis; Marian Hajduch
Journal:  Int J Mol Sci       Date:  2022-04-10       Impact factor: 6.208

6.  Transient metabolic improvement in obese mice treated with navitoclax or dasatinib/quercetin.

Authors:  Arantzazu Sierra-Ramirez; José Luis López-Aceituno; Luis Filipe Costa-Machado; Adrián Plaza; Marta Barradas; Pablo Jose Fernandez-Marcos
Journal:  Aging (Albany NY)       Date:  2020-06-25       Impact factor: 5.682

7.  Senolysis-Based Elimination of Chemotherapy-Induced Senescent Breast Cancer Cells by Quercetin Derivative with Blocked Hydroxy Groups.

Authors:  Anna Lewińska; Paweł Przybylski; Jagoda Adamczyk-Grochala; Dominika Błoniarz; Grzegorz Litwinienko; Maciej Wnuk
Journal:  Cancers (Basel)       Date:  2022-01-25       Impact factor: 6.639

Review 8.  Senolytics in the treatment of diabetic retinopathy.

Authors:  Jannah Waled Hassan; Ashay D Bhatwadekar
Journal:  Front Pharmacol       Date:  2022-08-26       Impact factor: 5.988

Review 9.  Senolytic drugs: from discovery to translation.

Authors:  J L Kirkland; T Tchkonia
Journal:  J Intern Med       Date:  2020-08-04       Impact factor: 13.068

10.  Therapy-Induced Senescence: Opportunities to Improve Anticancer Therapy.

Authors:  Pataje G Prasanna; Deborah E Citrin; Jeffrey Hildesheim; Mansoor M Ahmed; Sundar Venkatachalam; Gabriela Riscuta; Dan Xi; Guangrong Zheng; Jan van Deursen; Jorg Goronzy; Stephen J Kron; Mitchell S Anscher; Norman E Sharpless; Judith Campisi; Stephen L Brown; Laura J Niedernhofer; Ana O'Loghlen; Alexandros G Georgakilas; Francois Paris; David Gius; David A Gewirtz; Clemens A Schmitt; Mohamed E Abazeed; James L Kirkland; Ann Richmond; Paul B Romesser; Scott W Lowe; Jesus Gil; Marc S Mendonca; Sandeep Burma; Daohong Zhou; C Norman Coleman
Journal:  J Natl Cancer Inst       Date:  2021-10-01       Impact factor: 11.816

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.